Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 2

Conditions

Melanoma 69Leukemia, Myeloid, Acute 32Carcinoma, Renal Cell 27Neoplasm Metastasis 17Breast Neoplasms 16Leukemia 15Neuroblastoma 14Kidney Neoplasms 14Lymphoma, Non-Hodgkin 12Ovarian Neoplasms 11Carcinoma, Non-Small-Cell Lung 11Myelodysplastic Syndromes 10Recurrence 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Neoplasms 8Leukemia, Lymphocytic, Chronic, B-Cell 8Lymphoma 7Congenital Abnormalities 7Colorectal Neoplasms 7Leukemia, Myelogenous, Chronic, BCR-ABL Positive 6Skin Neoplasms 5Multiple Myeloma 5Lymphoma, Mantle-Cell 5Lymphoma, Follicular 5Head and Neck Neoplasms 5Fallopian Tube Neoplasms 5Carcinoma, Hepatocellular 5Rectal Neoplasms 4Mesothelioma, Malignant 4Lung Neoplasms 4

Interventions

Cyclophosphamide 3fludarabine 2Radiotherapy 2Interleukin-2 2tislelizumab 1pembrolizumab 1pazopanib 1patritumab deruxtecan 1palbociclib 1niraparib 1neotil 1lenvatinib 1atezolizumab 1Yoga 1X-Rays 1Watchful Waiting 1Tomography, X-Ray Computed 1Tiragolumab 1Surveys and Questionnaires 1Radiation 1Positron-Emission Tomography 1Nivolumab 1Magnetic Resonance Imaging 1Lacteol 1Ipilimumab 1High-Throughput Nucleotide Sequencing 1Fluorodeoxyglucose F18 1Data Collection 1Cryosurgery 1Celecoxib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Solid Tumor, Adult × Interleukin-2 × Clear all
NCT04643574 2025-02-14

NeoTIL in Advanced Solid Tumors

Centre Hospitalier Universitaire Vaudois

Phase 1 Active not recruiting
42 enrolled
Other solid neoplasm

Solid Tumor, Adult

NCT03992326 2021-03-18

Adoptive Transfer Of Autologous Tumor-Infiltrating Lymphocytes in Solid Tumors

Centre Hospitalier Universitaire Vaudois

Phase 1 Terminated
6 enrolled
Other solid neoplasm

Solid Tumor, Adult

Data powered by HemOnc (CC BY 4.0) Colophon âš¡